Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Inmune Bio Inc (INMB)

Inmune Bio Inc (INMB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 163,667
  • Shares Outstanding, K 17,946
  • Annual Sales, $ 180 K
  • Annual Income, $ -30,340 K
  • 60-Month Beta 1.91
  • Price/Sales 925.06
  • Price/Cash Flow N/A
  • Price/Book 2.39
Trade INMB with:

Options Overview Details

View History
  • Implied Volatility 103.67% ( -3.70%)
  • Historical Volatility 60.76%
  • IV Percentile 40%
  • IV Rank 18.82%
  • IV High 228.73% on 05/16/22
  • IV Low 74.69% on 01/11/22
  • Put/Call Vol Ratio 0.01
  • Today's Volume 77
  • Volume Avg (30-Day) 47
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 2,614
  • Open Int (30-Day) 2,476

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.73
  • Number of Estimates 1
  • High Estimate -0.73
  • Low Estimate -0.73
  • Prior Year -0.55
  • Growth Rate Est. (year over year) -32.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.53 +10.32%
on 07/27/22
10.75 -12.47%
on 08/05/22
-0.73 (-7.20%)
since 07/12/22
3-Month
4.63 +103.29%
on 05/24/22
10.75 -12.47%
on 08/05/22
+2.77 (+41.72%)
since 05/12/22
52-Week
4.63 +103.29%
on 05/24/22
30.37 -69.02%
on 09/07/21
-7.44 (-44.15%)
since 08/12/21

Most Recent Stories

More News
INmune Bio, Inc. (INMB) Q2 2022 Earnings Call Transcript

INMB earnings call for the period ending June 30, 2022.

INMB : 9.41 (+3.18%)
INmune Bio, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Company to Host Conference Call Today, August 3, at 4:30pm ET...

INMB : 9.41 (+3.18%)
INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 27, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc....

INMB : 9.41 (+3.18%)
INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alzheimer's Disease

Alzheimer's Association International Conference ("AAIC") – Systems Biology of Alzheimer's Disease Panel on August 4, 2022 Moderated by Jeffrey Cummings,...

INMB : 9.41 (+3.18%)
INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer

In pre-clinical models of trastuzumab resistant MUC4 HER2+ breast cancer, treatment with INB03™ decreases MUC4 expression, reverses resistance to...

INMB : 9.41 (+3.18%)
Can INmune Bio, Inc. (INMB) Climb 105% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 104.7% upside potential for INmune Bio, Inc. (INMB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

INMB : 9.41 (+3.18%)
New Analysts Initiate Coverage: 5 Stocks for Higher Returns

Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Malibu (MBUU), Cantaloupe (CTLP), INmune (INMB), Swedish Match (SWMAY) and GATX.

MBUU : 66.53 (+2.42%)
GATX : 102.65 (+1.99%)
INMB : 9.41 (+3.18%)
SWMAY : 10.4900 (-0.76%)
CTLP : 6.68 (+5.20%)
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study

The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.

BIIB : 220.99 (+1.27%)
AGLE : 0.4920 (-1.58%)
LPTX : 1.2900 (-0.77%)
INMB : 9.41 (+3.18%)
Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates

Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

REGN : 628.71 (+0.77%)
SNY : 44.37 (+2.19%)
ETTX : 2.19 (-0.45%)
INMB : 9.41 (+3.18%)
INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595™ in Alzheimer’s Disease

BOCA RATON, FL., May 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on...

INMB : 9.41 (+3.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system in cancer. The company's product platform consists of INKmune and INB03. INKmune is a natural killer cell therapeutic which primes the patient's NK cells to attack developing...

See More

Key Turning Points

3rd Resistance Point 9.79
2nd Resistance Point 9.64
1st Resistance Point 9.52
Last Price 9.41
1st Support Level 9.25
2nd Support Level 9.10
3rd Support Level 8.98

See More

52-Week High 30.37
Fibonacci 61.8% 20.54
Fibonacci 50% 17.50
Fibonacci 38.2% 14.46
Last Price 9.41
52-Week Low 4.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar